Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Rand Sutherland, MD, MPH, will deliver a presentation on Monday, January 13, 2025, at 2:15 p.m. PT.
The presentation will be accessible via live webcast through the 'Events' tab on the 'Investors' section of Upstream Bio's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.
Details
News Market Reaction – UPB
The recorded move for UPB in the trading session of this news was -7.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 p.m. PT.
A live webcast of the presentation will be available under the “Events” tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.